Certified by Founder Lodge
Evommune
United States - Palo Alto, California
START UP
1 Disclosed Funding Rounds $50,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life.
Many immunology-focused medications give pa
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| April, 27 ,2023 | Series B | $50,000,000 | |
| June, 29 ,2023 | Series B | $7,500,000.00 | |
| November, 01 ,2024 | Series C | $115,000,000.00 |
Andera Partners
EQT Life Sciences
Arix Bioscience plc
Amplitude Ventures
Symbiosis
Pivotal bioVenture Partners
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
